Human amylin (amidated) is a 37-amino acid peptide hormone co-released with insulin to control postprandial glucose by suppressing glucagon and slowing gastric emptying. Its amyloidogenic property, linked to beta-cell toxicity, makes it a critical research target for type 2 diabetes pathophysiology, enabling in vitro fibril formation studies and in vivo metabolic research.
